These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 10851509)
21. Low doses of rIL2 after autologous bone marrow transplantation induce a "prolonged" immunostimulation of NK compartment in high-grade non-Hodgkin's lymphomas. Raspadori D; Lauria F; Ventura MA; Tazzari PL; Ferrini S; Miggiano MC; Rondelli D; Tura S Ann Hematol; 1995 Oct; 71(4):175-9. PubMed ID: 7578523 [TBL] [Abstract][Full Text] [Related]
22. Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation. Foa R; Guarini A; Gillio Tos A; Cardona S; Fierro MT; Meloni G; Tosti S; Mandelli F; Gavosto F Cancer Res; 1991 Feb; 51(3):964-8. PubMed ID: 1988139 [TBL] [Abstract][Full Text] [Related]
23. [Immunotherapy with interleukin-2 and allogenic LAK cells in a patient with acute myeloblastic leukemia]. Parrado A; Casares S; Carmona M; Campo T; Rodríguez Fernández JM Sangre (Barc); 1994 Oct; 39(5):393-6. PubMed ID: 7754446 [TBL] [Abstract][Full Text] [Related]
24. Interleukin-2 before and/or after autologous bone marrow transplantation for pediatric acute leukemia patients. Messina C; Zambello R; Rossetti F; Gazzola MV; Varotto S; Destro R; Basso G; Semenzato G; Zanesco L Bone Marrow Transplant; 1996 May; 17(5):729-35. PubMed ID: 8733689 [TBL] [Abstract][Full Text] [Related]
25. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering. Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934 [TBL] [Abstract][Full Text] [Related]
26. Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma. Valteau-Couanet D; Rubie H; Meresse V; Farace F; Brandely M; Hartmann O Bone Marrow Transplant; 1995 Oct; 16(4):515-20. PubMed ID: 8528166 [TBL] [Abstract][Full Text] [Related]
27. Low-dose natural interleukin-2 and recombinant interferon-gamma following autologous bone marrow grafts in pediatric patients with high-risk acute leukemia. Baumgarten E; Schmid H; Pohl U; Brzoska J; Linderkamp C; Siegert W; Henze G Leukemia; 1994 May; 8(5):850-5. PubMed ID: 8182941 [TBL] [Abstract][Full Text] [Related]
28. Interleukin 2 immunotherapy in children with neuroblastoma after high-dose chemotherapy and autologous bone marrow transplantation. Favrot MC; Michon J; Floret D; Cochat C; Negrier S; Mathiot C; Coze C; Zucker JM; Franks CR; Bouffet E Pediatr Hematol Oncol; 1990; 7(3):275-84. PubMed ID: 2206868 [TBL] [Abstract][Full Text] [Related]
29. Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma. Gottlieb DJ; Prentice HG; Mehta AB; Galazka AR; Heslop HE; Hoffbrand AV; Brenner MK Br J Haematol; 1990 Aug; 75(4):499-505. PubMed ID: 2119792 [TBL] [Abstract][Full Text] [Related]
30. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy. Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686 [TBL] [Abstract][Full Text] [Related]
31. Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow. Almici C; Manoni L; Carlo-Stella C; Garau D; Cottafavi L; Rizzoli V Bone Marrow Transplant; 1995 Jul; 16(1):95-101. PubMed ID: 7581136 [TBL] [Abstract][Full Text] [Related]
32. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival. Yang RK; Kalogriopoulos NA; Rakhmilevich AL; Ranheim EA; Seo S; Kim K; Alderson KL; Gan J; Reisfeld RA; Gillies SD; Hank JA; Sondel PM Cancer Immunol Immunother; 2013 Aug; 62(8):1303-13. PubMed ID: 23661160 [TBL] [Abstract][Full Text] [Related]
33. Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice. Castriconi R; Dondero A; Cilli M; Ognio E; Pezzolo A; De Giovanni B; Gambini C; Pistoia V; Moretta L; Moretta A; Corrias MV Cancer Immunol Immunother; 2007 Nov; 56(11):1733-42. PubMed ID: 17426969 [TBL] [Abstract][Full Text] [Related]
34. Natural killer (NK) and T cell-associated surface marker expression following allogeneic and autologous bone marrow transplantation (BMT). Nagler A; Rabinowitz R; Rosengolts-Rat J; Condiotti R; Schlesinger M J Hematother Stem Cell Res; 2000 Feb; 9(1):63-75. PubMed ID: 10738973 [TBL] [Abstract][Full Text] [Related]
35. [LAK cells and immunotherapy of cancer]. Khayat D; Weil M; Soubrane C; Jacquillat C Bull Cancer; 1988; 75(1):3-7. PubMed ID: 3258774 [TBL] [Abstract][Full Text] [Related]
36. NK cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT. Kanold J; Paillard C; Tchirkov A; Lang P; Kelly A; Halle P; Isfan F; Merlin E; Marabelle A; Rochette E; Deméocq F Pediatr Blood Cancer; 2012 Oct; 59(4):739-42. PubMed ID: 22180305 [TBL] [Abstract][Full Text] [Related]
37. [Allogenic bone marrow transplantation versus autograft in acute lymphoblastic leukemia, in second remission in 113 children. Results of the Grupo Español de Transplante de Medula Niños (GETMON)]. Badell I; Ortega JJ; Muñoz A; Bureo E; Madero L; Olivé T; Cubells J; Maldonado MS; Baro J; Díaz MA Sangre (Barc); 1996 Apr; 41(2):101-8. PubMed ID: 9045349 [TBL] [Abstract][Full Text] [Related]
38. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer. Lee K; O'Donnell RW; Cockett AT J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620 [TBL] [Abstract][Full Text] [Related]
39. Immunotherapy with IL2 by constant infusion and weekly doxorubicin. Paciucci PA; Bekesi JG; Ryder JS; Odchimar R; Chahinian PA; Holland JF Am J Clin Oncol; 1991 Aug; 14(4):341-8. PubMed ID: 1830717 [TBL] [Abstract][Full Text] [Related]
40. Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation. de la Rubia J; Sanz GF; Martín G; Sempere A; Picón I; Carral A; Larrea L; Martínez J; Soler MA; Bonanad S; López F; Jarque I; Sanz MA Bone Marrow Transplant; 1996 Dec; 18(6):1167-73. PubMed ID: 8971390 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]